ProPhase Labs (NASDAQ:PRPH) Stock Passes Above Two Hundred Day Moving Average of $5.02

ProPhase Labs, Inc. (NASDAQ:PRPH)’s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $5.02 and traded as high as $5.35. ProPhase Labs shares last traded at $5.31, with a volume of 44,554 shares trading hands.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of ProPhase Labs in a report on Wednesday, February 21st.

ProPhase Labs Price Performance

The firm has a market cap of $97.83 million, a price-to-earnings ratio of -5.53 and a beta of -0.17. The stock’s 50-day moving average price is $5.54 and its 200 day moving average price is $5.03. The company has a quick ratio of 2.10, a current ratio of 2.28 and a debt-to-equity ratio of 0.29.

ProPhase Labs (NASDAQ:PRPH) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.51) EPS for the quarter. The firm had revenue of $3.50 million during the quarter, compared to the consensus estimate of $10.71 million. ProPhase Labs had a negative return on equity of 29.83% and a negative net margin of 37.81%. Equities research analysts predict that ProPhase Labs, Inc. will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its position in shares of ProPhase Labs by 50.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock worth $68,000 after purchasing an additional 5,026 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of ProPhase Labs during the third quarter worth approximately $756,000. Finally, SVB Wealth LLC bought a new position in shares of ProPhase Labs in the third quarter valued at approximately $208,000. Institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.